Protagenic Therapeutics, Inc.
PTIX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $6 | $14 | $1 | $45 |
| - Cash | $3 | $4 | $1 | $2 |
| + Debt | $3 | $4 | $0 | $0 |
| Enterprise Value | $7 | $13 | $1 | $43 |
| Revenue | $0 | $0 | $0 | -$0 |
| % Growth | – | – | 100% | – |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | 200% |
| EBITDA | -$1 | -$5 | -$1 | -$2 |
| % Margin | – | – | – | 6,128.9% |
| Net Income | -$1 | -$5 | -$1 | -$2 |
| % Margin | – | – | – | 6,180.6% |
| EPS Diluted | -0.47 | -1.37 | -2.75 | -0.24 |
| % Growth | 65.7% | 50.2% | -1,045.8% | – |
| Operating Cash Flow | -$1 | -$1 | -$1 | -$1 |
| Capital Expenditures | $0 | $0 | -$0 | $0 |
| Free Cash Flow | -$1 | -$1 | -$1 | -$1 |